Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ALX Oncology Holdings ( (ALXO) ) has provided an update.
On January 22, 2025, ALX Oncology announced the appointment of Harish Shantharam as Chief Financial Officer and the addition of Barbara Klencke and Chris Takimoto to its Board of Directors. These appointments are expected to strengthen the company’s leadership as it advances its lead candidate, evorpacept, into late-stage clinical trials in 2025. Shantharam brings extensive experience in finance and commercial operations from his previous roles at CymaBay Therapeutics and Gilead Sciences. Dr. Klencke and Dr. Takimoto are highly regarded oncology leaders with significant contributions to oncology drug development, and their inclusion is anticipated to enhance ALX Oncology’s strategic direction and innovation in immuno-oncology.
More about ALX Oncology Holdings
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on advancing therapies that enhance the immune system to treat cancer and extend patients’ lives. Its lead therapeutic candidate, evorpacept, is being evaluated across multiple clinical trials for various cancer indications.
YTD Price Performance: 5.77%
Average Trading Volume: 1,027,616
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $87.03M
See more insights into ALXO stock on TipRanks’ Stock Analysis page.
